Sanofi Slams Mylan's 'Mishmash' Of Claims Over Insulin
Sanofi-Aventis U.S. is asking a Pennsylvania federal court to toss Mylan Pharmaceuticals' claims that Sanofi abused discounts and patent litigation to keep Mylan's generic injectable insulin off the market, arguing Mylan's...To view the full article, register now.
Already a subscriber? Click here to view full article